COMP <GO>
NAMS vs MBX // OPERATING MARGIN
NewAmsterdam Pharma Company N.V. (NASDAQ) VS. MBX Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: NAMS 1
— MBX 4
■ METRIC PARITY
LAST: $20.76 (-1.47%) • MKT CAP: $2.48B
operating-margins
-60.00%
LAST: $54.54 (+0.70%) • MKT CAP: $2.63B
operating-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NAMS VS. MBX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NAMS | MBX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -26.40% | -8.60 | MBX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.96% | -3.12% | -2.84 | MBX | /fcf-yield <GO> |
| Operating Margin ACTIVE | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -50.60% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 15.94 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | NAMS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.7 | 53.8 | -13.13 | MBX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.48B | $2.63B | -$145.1M | MBX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NAMS REV | MBX REV | NAMS GROSS % | MBX GROSS % | NAMS FCF | MBX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $22.5M | $0 | — | — | -$147.8M | -$81.9M |
| FY 2024 | $45.6M | $0 | — | — | -$158.6M | -$55.6M |
| FY 2023 | $14.1M | $0 | — | — | -$141.2M | -$32.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NAMS // BETA —
MBX // BETA —